Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (73) Arrow Down
Filter Results: (73) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (73)
    • News  (28)
    • Research  (34)
    • Multimedia  (1)
  • Faculty Publications  (24)

Show Results For

  • All HBS Web  (73)
    • News  (28)
    • Research  (34)
    • Multimedia  (1)
  • Faculty Publications  (24)
Page 1 of 73 Results →
  • January 17, 2022
  • Article

Reducing Racial Disparities in Cancer Outcomes

By: Kathy Giusti and Richard G. Hamermesh
A disproportionate number of Black patients die from cancer in the United States. A key to addressing this problem is enrolling more Black patients in clinical trials. A strategy consisting of these three parts can help accomplish this goal: 1) centralize information... View Details
Keywords: Cancer Trials; Racial Disparity; Health Testing and Trials; Race; Strategy
Citation
Read Now
Related
Giusti, Kathy, and Richard G. Hamermesh. "Reducing Racial Disparities in Cancer Outcomes." Harvard Business Review (website) (January 17, 2022).
  • September 2017 (Revised July 2023)
  • Case

Adaptive Platform Trials: The Clinical Trial of the Future?

By: Ariel D. Stern and Sarah Mehta
In July 2017, Dr. Brian M. Alexander, president and CEO of the AGILE Research Foundation, was preparing to launch a new type of clinical trial—an adaptive platform trial—to study potential therapies for glioblastoma (GBM), an aggressive form of brain cancer.... View Details
Keywords: Clinical Trials; Cancer; Adaptive Platform Trials; Platform Trials; Adaptive Trials; Glioblastoma; Health; Health Care and Treatment; Health Testing and Trials; Business Strategy; Innovation Strategy; Health Industry; United States
Citation
Educators
Purchase
Related
Stern, Ariel D., and Sarah Mehta. "Adaptive Platform Trials: The Clinical Trial of the Future?" Harvard Business School Case 618-025, September 2017. (Revised July 2023.)
  • March 2018
  • Teaching Note

Adaptive Platform Trials: The Clinical Trial of the Future?

By: Ariel D. Stern and Sarah Mehta
This teaching note provides guidance and recommendations for teaching HBS Case No. 618-025, entitled “Adaptive Platform Trials: The Clinical Trial of the Future?” View Details
Keywords: Clinical Trials; Drug Trials; Drug Testing; Cancer Trials; Glioblastoma; Platform Trials; Adaptive Trials; Adaptive Platform Trials; Health Testing and Trials; Health Care and Treatment; Business Strategy; Health Industry; United States
Citation
Purchase
Related
Stern, Ariel D., and Sarah Mehta. "Adaptive Platform Trials: The Clinical Trial of the Future?" Harvard Business School Teaching Note 618-048, March 2018.
  • July 2021
  • Supplement

Adaptive Platform Trials: The Clinical Trial of the Future? (C)

By: Ariel D. Stern and Sarah Mehta
This (C) case provides an update on the work of the Global Coalition for Adaptive Research (GCAR) and also illustrates how adaptive platform trials can nimbly respond to a global pandemic. View Details
Keywords: Clinical Trials; Drug Trials; Drug Testing; Cancer Trials; Glioblastoma; Platform Trials; Adaptive Trials; Adaptive Platform Trials; Health Testing and Trials; Health Care and Treatment; Business Strategy; Health Industry; United States
Citation
Purchase
Related
Stern, Ariel D., and Sarah Mehta. "Adaptive Platform Trials: The Clinical Trial of the Future? (C)." Harvard Business School Supplement 622-012, July 2021.
  • September 2019
  • Supplement

Adaptive Platform Trials: The Clinical Trial of the Future? (B)

By: Ariel D. Stern and Sarah Mehta
This case provides an update to the (A) case, which introduces students to adaptive platform trials, an ambitious, more efficient type of clinical trial that increases access to therapies. The (A) case centers on Dr. Brian Alexander’s efforts to launch an adaptive... View Details
Keywords: Clinical Trials; Drug Trials; Drug Testing; Cancer Trials; Glioblastoma; Platform Trials; Adaptive Trials; Adaptive Platform Trials; Health Testing and Trials; Health Care and Treatment; Financing and Loans; Business Strategy; Health Industry; United States
Citation
Purchase
Related
Stern, Ariel D., and Sarah Mehta. "Adaptive Platform Trials: The Clinical Trial of the Future? (B)." Harvard Business School Supplement 620-001, September 2019.
  • September 2020
  • Case

Minerva 2020: Clinical Trials

By: John R. Wells and Benjamin Weinstock
In March 2020, Dr. Cynthia Bamdad, founder and CEO of Minerva Biotechnologies Inc. (Minerva), was reviewing the first results of human clinical trials for the company’s novel CAR-T drug therapeutic, one of the first ever to target solid cancer tumors. The results... View Details
Keywords: Biotechnology; Strategic Decision Making; Entrepreneurship; Health Testing and Trials; Decision Choices and Conditions; Strategy
Citation
Educators
Purchase
Related
Wells, John R., and Benjamin Weinstock. "Minerva 2020: Clinical Trials." Harvard Business School Case 721-391, September 2020.
  • 22 Feb 2024
  • News

Combat-Tested Cancer Coaching

reflect and focus on what really mattered. That journaling lasted 26 years, tracking Giusti’s successful battle with multiple myeloma. Those entries and Giusti’s reflections on them are at the heart of her new book, Fatal to Fearless: 12 Steps to Beating View Details
  • 08 Mar 2018
  • News

Could a New Business Model Make Clinical Drug Trials More Accessible to Patients?

  • July 2011 (Revised September 2012)
  • Case

Intraoperative Radiotherapy for Breast Cancer (A)

By: Willy Shih
"This trial is going to take longer." Those were words that Michael Kaschke, CEO of Carl Zeiss AG, was not surprised to hear as he nurtured the intraoperative radiotherapy business inside his company's microsurgery unit. But he also didn't expect it to take 13 years to... View Details
Keywords: Finance; Business History; Disruptive Innovation; Emerging Markets; Organizational Change and Adaptation; Research and Development; Safety
Citation
Educators
Purchase
Related
Shih, Willy. "Intraoperative Radiotherapy for Breast Cancer (A)." Harvard Business School Case 612-003, July 2011. (Revised September 2012.)
  • 15 Jan 2018
  • News

A Better Business Model for Fighting Cancer

Keywords: Scientific Research and Development Services
  • 12 Dec 2022
  • Research & Ideas

Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them

example that could inform change is in the successful representation of minorities in tests for novel HIV/AIDS drugs. Black patients make up roughly 30 percent of the patients taking part in clinical trials for these medicines, compared... View Details
Keywords: by Scott Van Voorhis; Pharmaceutical; Health
  • 23 Feb 2017
  • News

The power — and the fear — of knowing your cancer genome

  • Article

Decisions about Medication Use and Cancer Screening across Age Groups in the United States

By: Kathleen M. Fairfield, Bethany S. Gerstein, Carrie A. Levin, Vickie Stringfellow, Heidi Wierman and Mary McNaughton-Collins
Objective
To describe decision process and quality for common cancer screening and medication decisions by age group.

Methods
We included 2941 respondents to a national Internet survey who made at least one decision about colorectal, breast,... View Details
Keywords: Screening; Decision Making; Health Care and Treatment; Health Testing and Trials
Citation
Find at Harvard
Related
Fairfield, Kathleen M., Bethany S. Gerstein, Carrie A. Levin, Vickie Stringfellow, Heidi Wierman, and Mary McNaughton-Collins. "Decisions about Medication Use and Cancer Screening across Age Groups in the United States." Patient Education and Counseling 98, no. 3 (March 2015): 338–343.
  • November 2018
  • Case

David Hysong and SHEPHERD Therapeutics

By: Ananth Raman, John Masko and Aldo Sesia
In 2016, David Hysong, at age 27, found out he had a rare, incurable cancer. Rather than wait around to die, Hysong, a recent graduate of Harvard Divinity School, decided to launch a biotechnology company called Shepherd Therapeutics to development treatments for his... View Details
Keywords: Cancer; Therapeutics; Drugs; Health Care and Treatment; Business Startups; Product Development; Financing and Loans; Growth and Development Strategy; Problems and Challenges
Citation
Educators
Related
Raman, Ananth, John Masko, and Aldo Sesia. "David Hysong and SHEPHERD Therapeutics." Harvard Business School Case 619-012, November 2018.
  • 24 Apr 2014
  • News

Finding a cure for cancer became a personal mission

Thai Lee (MBA 1985), president and CEO of SHI International, talks about how a family crisis led her to funding cancer research. (Published April 2014) View Details
  • July 2021 (Revised July 2022)
  • Case

Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care

By: Robert S. Kaplan, Navraj S. Nagra and Syed S. Shehab
Dr. Andrea Pusic, breast cancer reconstruction surgeon, wants to extend outcomes measurement beyond traditional surgical metrics of infections, complications, and survival rates. The case describes her development of a new mobile phone app, which collects patients’... View Details
Keywords: Health Care and Treatment; Outcome or Result; Cost Management; Activity Based Costing and Management; Mobile and Wireless Technology; Health Testing and Trials; Surveys; Health Industry; Boston
Citation
Educators
Purchase
Related
Kaplan, Robert S., Navraj S. Nagra, and Syed S. Shehab. "Brigham & Women's Hospital: Using Patient Reported Outcomes to Improve Breast Cancer Care." Harvard Business School Case 122-010, July 2021. (Revised July 2022.)
  • 24 Apr 2014
  • News

Giving hope and inspiration to cancer patients around the globe

data and share it globally. The organization also spearheads a clinical network of 16 research centers to conduct early-phase clinical trials faster and more efficiently. By applying business principles to the scientific field, Giusti has... View Details
  • 16 Jul 2019
  • News

The Making of a Movement

cancers.” Hundreds of millions of dollars later, there is no doubt that strategy has worked. Most important, those donations have had a tangible impact. “One hundred percent of the money funds rare cancer research and clinical View Details
Keywords: Greg Forbes Siegman; cancer
  • June 2014 (Revised February 2017)
  • Case

Kathy Giusti and the Multiple Myeloma Research Foundation

By: Richard G. Hamermesh, Joshua D. Margolis and Matthew G. Preble
What do you do when your rising professional career is cut short by an unexpected cancer diagnosis? Kathy Giusti shifted careers, built a new organization that transformed how cancer research is done, and now faces the challenge of sustaining the organization and its... View Details
Keywords: Philanthropy; Philanthropy Funding; Entrepreneurship; Health Care; Management Styles; Personalized Medicine; Health Care Outcomes; Cancer; Cancer Care In The U.S.; Personal Care; Leadership; Leading Change; Social Entrepreneurship; Philanthropy and Charitable Giving; Health Care and Treatment; Leadership Style; Management Style; Management Skills; Growth and Development Strategy; Business Strategy; Health; Health Industry; United States; Canada; Spain
Citation
Educators
Purchase
Related
Hamermesh, Richard G., Joshua D. Margolis, and Matthew G. Preble. "Kathy Giusti and the Multiple Myeloma Research Foundation." Harvard Business School Case 814-026, June 2014. (Revised February 2017.)
  • October 2013
  • Case

FasterCures: Removing Barriers to Treatments

By: Richard G. Hamermesh and James Weber

In mid-2013, as FasterCures celebrated its 10th anniversary as a center of the Milken Institute, Executive Director Margaret Anderson thought about what the organization should do to ensure it had even more impact in its next 10 years. FasterCures was a non-profit... View Details

Keywords: Health Care; Health Care Industry; Health Care Policy; Health Services; Healthcare; Healthcare Reform; Healthcare Ventures; Nonprofit; Non-profit Management; Not-for-profit; Incubator; Accelerator; Venture Philanthropy; Medical Services; Medical Solutions; Medical Research; Medical Treatment; Clinical Trials; Drug Reimbursement; Early Stage; Early Stage Research Funding; Early Stage Funding; Milken Institute; Michael Milken; David Baltimore; Partnering For Cures; National Institutes Of Health; Cancer Care In The U.S.; Cancer Care Services; Policy-making; Health Care and Treatment; Health; Health Testing and Trials; Entrepreneurship; Social Entrepreneurship; Nonprofit Organizations; Policy; Health Industry; United States; District of Columbia
Citation
Educators
Purchase
Related
Hamermesh, Richard G., and James Weber. "FasterCures: Removing Barriers to Treatments." Harvard Business School Case 814-003, October 2013.
  • 1
  • 2
  • 3
  • 4
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.